Skip to main content
. 2021 Oct 30;54:101365. doi: 10.1016/j.molmet.2021.101365

Figure 4.

Figure 4

Clinical trials with drugs that can target the UPR pathway components in T1D. Imatinib, a tyrosine kinase inhibitor, may blunt IRE1α′s hyperactivation and inhibit pro-apoptotic pathways in β-cells. Verapamil, a calcium channel blocker, may decrease expression of TXNIP that otherwise promotes apoptosis by increasing oxidative stress and inflammasome formation in β-cells. TUDCA alleviates ER stress in β-cells in an ATF6-dependent manner.